How NIH Funds CROs: A Guide to SBIR for Contract Research Organizations
NIH will pay a small CRO to build its next service. The SBIR program funds the research to develop a new assay, model, platform or method, and the CRO keeps it and sells it to clients. Companies like EpiCypher, Integral Molecular and Litron Laboratories have built much of their business this way.
Most CROs never apply because they assume SBIR is for drug developers. This guide is for owners, CSOs and BD leads at small US CROs. It covers what NIH has funded before, what you could propose, and how Phase I and Phase II work from a CRO's side of the table.
Why NIH funds CROs
NIH funds research that leads to something people will buy, and a better research service counts. The SBIR program does not require a drug or a device. New assays, animal and cell models, screening platforms and analytical methods are funded every cycle because NIH-funded scientists and drug developers need them.
The line that matters is simple:
Fundable: developing and validating a capability you don't have yet, such as a new assay, model, readout or platform.
Not fundable: running studies for paying clients, or doing work you could already sell today.
Commercialization for a CRO usually means selling the new capability as a service. A kit, a reagent or a license works too. NIH reviewers accept fee-for-service revenue as a commercial path, as long as you can show who will pay for it and why.
Small CROs also start with advantages most applicants lack: working labs, experienced scientists, preliminary data, and paying customers who can say they want the new service.
What NIH has already funded
At least 13 service companies have used NIH SBIR to build what they now sell, from about $2 million to about $85 million each. Totals below are approximate NIH SBIR/STTR funding to date.
EpiCypher (genomics services and reagents, NC), about $85M: chromatin profiling assays.
Integral Molecular (antibody discovery, Philadelphia), about $34M: a specificity screen now used by 250+ biopharma companies.
Litron Laboratories (genetic toxicology, Rochester, NY), about $21M: tox tests, one of which became an international regulatory guideline.
PsychoGenics (in vivo / CNS pharmacology, NJ), about $18M: high-throughput in vivo drug screening.
TissueVision (imaging and histology), about $16M: automated 3D whole-organ imaging for drug studies.
Altis Biosystems (human cell models, NC), about $12M: drug-screening models of the human intestine.
Reaction Biology (in vitro assays, PA), about $10M: new assay panels it now sells as services.
Organix (medicinal chemistry), about $7M: its own chemistry programs.
ingenious targeting laboratory (animal model generation), about $4.5M: new mouse models.
ImQuest BioSciences (infectious disease), about $3.6M: antiviral and microbicide candidates.
NanoImaging Services (cryo-EM / structural biology, San Diego), about $3M: a microED pipeline for pharma clients.
Sus Clinicals (oncology and large-animal models), about $2.4M: validation of its Oncopig cancer models.
Panome Bio (mass spec / metabolomics), a $2M Phase II: biomarker discovery methods.
The pattern is consistent. Each company proposed a capability the research market lacked, used Phase I to prove it worked, and used Phase II to make it a product. Many then won follow-on awards for the next service.
Totals are rounded from NIH RePORTER (SBIR and STTR activity codes) and may include awards to related entities.
What your CRO could propose
The best project is the service your clients keep asking for that you can't offer yet. Start there, then check that it solves a problem for a disease area NIH cares about.
In vivo pharmacology: a new disease model, or automated behavioral or physiological readouts (precedent: PsychoGenics).
Oncology models: better-predicting PDX, syngeneic or large-animal tumor models (Sus Clinicals).
Toxicology / safety: a faster or more human-relevant tox assay that could support regulatory submissions (Litron Laboratories).
In vitro assays: a new target-class panel or a higher-throughput format (Reaction Biology).
Antibody services: a new discovery, screening or specificity platform (Integral Molecular).
Cell models: human iPSC, organoid or tissue-chip models for a specific organ (Altis Biosystems).
Genomics: a new sequencing-based assay or a lower-input method (EpiCypher).
Bioanalytical / mass spec: a new biomarker panel or a method for hard-to-measure analytes (Panome Bio).
Imaging / histology: automated imaging or AI-based quantitation (TissueVision).
Structural biology: a new structure method or pipeline for difficult targets (NanoImaging Services).
Model generation: new genetically engineered or humanized animal models (ingenious targeting laboratory).
A strong CRO project usually has three things:
A clear gap: researchers can't get this measurement or model today, or only at a cost or speed that limits their work.
A health link: the capability speeds up research or drug development in a disease area an NIH institute funds.
Proof of demand: clients or partners willing to write letters saying they would use and pay for it.
How it works: Phase I and Phase II
Phase I proves your new capability works; Phase II builds it into something you can sell. Each phase is a separate grant with its own application and review.
Can your CRO apply? Most small independent CROs can. You need to be a for-profit US company with 500 or fewer employees, including affiliates, and majority-owned by US citizens or permanent residents. The project lead (PI) must be primarily employed by your company. CROs owned by a large parent or a non-US group usually do not qualify.
Phase I: feasibility
Purpose: show the new assay, model or method works.
Budget: $323,090 guideline (total costs); higher on some institute waiver topics.
Length: 6 months to 2 years.
Work done by your company: at least two-thirds.
Phase II: development
Purpose: validate, scale and get it ready to sell.
Budget: $2,153,927 guideline (total costs); higher on some institute waiver topics.
Length: 1 to 3 years.
Work done by your company: at least half.
Reviewers weigh: your Phase I results, the approach, and a full commercialization plan.
Ways in
Standard path: apply for Phase I, then apply for Phase II once you have results.
Fast-Track: apply for both phases in one application. Phase II funding starts once you hit pre-agreed Phase I milestones, which avoids a funding gap.
Direct to Phase II: skip Phase I if you already have feasibility data from your own work. This often fits CROs with strong internal pilot data.
After Phase II: NIH offers later-stage awards, including the new Phase IIB Strategic Breakthrough award, which requires matching private funding.
Timing. Standard due dates are January 5, April 5 and September 5. Expect about 6 to 9 months from submission to funding.
Program status. Congress reauthorized SBIR in April 2026 through September 2031, after a six-month lapse. HHS now limits each company to nine SBIR/STTR submissions per fiscal year, so pick projects carefully. Budget limits vary by institute and topic, so check the current solicitation before you build a budget.
Where CRO applications go wrong
CRO applications rarely fail on the science. They fail when the project reads like client work, or when the business side isn't ready for a federal grant.
It reads like a service contract. Frame the project as research with open questions and measurable go/no-go milestones, not a study plan you already know how to run.
Client data or IP is tangled in. Don't build the project on a client's compounds, samples or confidential data. Check your master service agreements for clauses that give clients rights to methods you develop.
The significance is about your business, not health. Reviewers fund what advances research on a disease. Lead with the scientific bottleneck, then show your service removes it.
No evidence of demand. Letters from clients, pharma partners or academic labs saying they would use and pay for the service carry a lot of weight.
Staff time is double-counted. Scientists who also bill client work need timekeeping that separates grant effort from billable hours. The PI must meet the primary-employment rule.
Accounting isn't grant-ready. You need to track grant costs apart from client revenue and support your indirect rate. NIH also allows a fee (profit) of up to 7% on SBIR awards, which many first-time applicants forget to request.
Registrations aren't done. SAM.gov, Grants.gov, eRA Commons and the SBA company registry can take several weeks. Start them a month or more before the deadline.
Frequently asked questions
Who owns what we build?
You do. Under SBIR you keep the rights to your inventions and data; the government gets a limited license for its own use.
Can we keep serving clients during the grant?
Yes. The grant pays for the development project, and your client business continues alongside it. Keep the costs and staff time separate.
Can we sell the service while it's still grant-funded?
Selling the finished capability is the goal. Selling results from grant-funded work to a client during the project needs care, so plan it with your grants advisor.
Do we need an academic partner?
No. SBIR lets your company do the work. If a university collaborator does a large share of the research, the related STTR program may fit better.
We have a parent company. Are we eligible?
It depends on the parent's size and ownership. Affiliates count toward the 500-employee limit, so check before you invest time in an application.
How long does an application take to write?
Plan on 6 to 8 weeks for a Phase I, including registrations, letters of support and the budget.
Talk it through with us
In a free 20-minute call, we'll tell you whether your CRO is eligible, which of your service ideas could fit NIH, and which deadline makes sense. BW&CO helps small companies win non-dilutive funding, including NIH SBIR.
Book a free 20-minute CRO funding call
Sources
NIH RePORTER: award totals for the companies above
NIH SEED: Understanding SBIR and STTR: budget guidelines and project periods
Crowell & Moring: SBIR/STTR programs reauthorized after six-month lapse